20 articles
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
Small pilot study examined psilocybin's effects on brain circuits and emotion processing in healthy adults to understand abuse potential.
Small study reveals BDNF genetic variant could influence exercise's cognitive and cardiovascular benefits in healthy men.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
A completed pharmacokinetic study tracks NAD precursors NR and NMN from bloodstream to brain, filling a critical gap in human data.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
Completed study of 102 older adults tested whether combined interventions can preserve brain volume and improve mobility through muscle-brain axis.
French researchers followed 1,028 people with mild cognitive complaints to understand how dementia develops over time.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Eight-week mindfulness program tested for women experiencing severe menopause symptoms after preventive ovary removal surgery.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
A Columbia University trial tests whether a hip hop-based dementia education program builds lasting literacy and reduces stigma in children and families.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
